Evaluate the Knowledge and Understanding of Anesthesiologists Use of BRIDION® solution for injection, 100 mg/mL sugammadex (as sugammadex sodium) in Canada

Study identification

• EU PAS number:
  EUPAS24076
• Study ID:
  29547
• Official title and acronym:
  Evaluate the Knowledge and Understanding of Anesthesiologists Use of BRIDION® solution for injection, 100 mg/mL sugammadex (as sugammadex sodium) in Canada
• DARWIN EU® study:
  No
• Study countries:
  Canada
• Study description:
  This is an observational, cross-sectional survey of anesthesiologists in Canada to assess the level of understanding of the safe and appropriate use of BRIDIONTM. This knowledge and understanding (KAU) survey will help ensure the appropriate use of BRIDIONTM and evaluate the effectiveness of Merck-sponsored educational programs related to BRIDIONTM. The main objective of this study is to assess how anesthesiologists in Canada use BRIDIONTM as well as to evaluate how well anesthesiologists in Canada understand the safety and efficacy aspects of BRIDIONTM when administered to adult patients undergoing surgery.
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Actual:24/04/2017

Study start date

Planned:31/07/2018

Actual:31/07/2018

Data analysis start date

Planned:02/10/2018

Actual:04/10/2018

Date of final study report

Planned:31/12/2018

Actual:19/12/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Merck Sharp & Dohme Corp.

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only